Written Question·Department of Health and Social Care·UIN 7074

Achondroplasia: Vosoritide

Tabled: 4 October 2024

Answered: 14 October 2024

Question

Victoria Collins

Liberal Democrat — Harpenden and Berkhamsted

To ask the Secretary of State for Health and Social Care, for what reason vosoritide is not available for the treatment of achondroplasia in children.

Answer

Karin Smyth

Voxzogo has not been licensed by the Medicines and Healthcare products Regulatory Agency (MHRA). Should an application for Voxzogo, or any product containing the active ingredient vosoritide, be received, the MHRA will consider this accordingly, with rega...

ⓘ

This is an extract from the Parliament API. Search the full answer on Parliament.uk (UIN 7074) →